stockrowAlcon
ALC Healthcare Medical Instruments & Supplies
Alcon’s revenue for fiscal 2025 (year ended December 2025) was $10.4 billion, up 4.94% from fiscal 2024.
- Revenue
- +8.74%
- EPS
- −100.0%
- Free cash flow
- −0.54%
- Total debt
- −0.55%
Quarter to June 2026, against a year earlier
Follow ALC
Alert me
Alcon (ALC) Return on equity
Alcon's return on equity over the twelve months to 30 June 2026 was 2.94%, down 1.6 percentage points from fiscal 2025 (4.50%). Over the past ten years it has ranged from −3.13% (fiscal 2019) to 4.83% (fiscal 2024); the current reading is higher than 80% of that period. That is above the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 4.50% | (0.33) |
| FY2024 | 4.83% | 0.00 |
| FY2023 | 4.83% | 3.11 |
| FY2022 | 1.72% | (0.25) |
| FY2021 | 1.97% | 4.76 |
| FY2020 | −2.79% | 0.34 |
| FY2019 | −3.13% | (2.13) |
| FY2018 | −1.00% | (2.12) |
| FY2017 | 1.12% | 1.83 |
| FY2016 | −0.71% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| RMD ResMed Inc. compare | 26.4% |
| WST West Pharmaceutical Services, Inc. compare | 21.2% |
| COO The Cooper Companies, Inc. compare | 6.84% |
| BDX Becton, Dickinson and Company compare | 3.77% |
| SOLV Solventum Corporation compare | 3.19% |
| MDLN Medline Inc. compare | 3.18% |
| ALC Alcon | 2.94% |
| ALGN Align Technology, Inc. compare | 0.00% |
| BAX Baxter International Inc. compare | −10.6% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ALC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement